A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 6, 2005, Pages 468-472

  Deming, Dustin A ^a   Stella, Amy L ^a   Holen, Kyle D ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LACTATE DEHYDROGENASE; LONG ACTING DRUG; OCTREOTIDE; OXYGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPNEA; HOSPITAL ADMISSION; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; PROGNOSIS; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; DYSPNEA; HEPATITIS C; HUMANS; INJECTIONS, INTRAMUSCULAR; LIVER CIRRHOSIS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE;

EID: 26044469361     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society, Inc; 2004.
2. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 1998;25:751-755.
3. Leung T, Johnson P. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-520.
4. Soini Y, Virkajarvi N, Raunio H, Paakko P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker for prognosis. J Clin Pathol 1996;49:470-473.
5. Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res. 1999;19:3853-3856.
6. Jin J, Huang M, Wei HL, Liu GT. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel-7402. World Gastroenterol. 2002;8:1029-1034.
7. Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDRI gene and P-glycoprotein in hepatocellular carcinoma. J Natl Cancer Inst. 1992;84:262-264.
8. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984;68:487-491.
9. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002;94:3186-3191.
10. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78:34-39.
11. Yoshida T, Okazaki N, Yoshida T, et al. Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer. 1990;26:545-546.
12. Falkson G, Ryan LM, Johnson LA, et al. A randomized phase II study of mitoxantrone and cisplatin in hepatocellular cancer: an ECOG study. Cancer. 1987;60:2141.
13. Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993;50:22-26.
14. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatoceflular carcinoma. Cancer. 2001;91:101-105.
15. Shiu W, Mok SD, Leung N, et al. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol. 1987;17:113-115.
16. Yoshino, M, Okazaki N, YoshidaT, et al. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol. 1989;19:120-122.
17. Shin W, Mok SD, O SK, et al. Phase II trial of epirubicin in hepatoma. Cancer Treat Rep. 1986;70:1035-1036.
18. Harvey WH, Fleming TR, Beltran G, et al. Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. Cancer Treat Rep. 1987;71:1111-1112.
19. Lin J, Shiu W, Leung WT, et al. Phase II study of high-dose ifosfamide in hepatocellular carcinoma. Cancer Chemother Pharmacol. 1993;31:338-339.
20. Falkson G, Burger W. A phase II trial of vindesine in hepatocellular cancer. Oncology. 1995;52:86-87.
21. Chao Y, Chan WL, Huang YS, et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer. 1996;77:635-639.
22. Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:277-281.
23. Part YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421-427.
24. Tetf M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest. 1995;13:460-463.
25. Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and α-interferon therapy of advanced hepatocellular carcinoma. Cancer. 1993;71:2187-2190.
26. Yang TS, Wang CH, Hsieh RK, et al. Gemcitabine and doxorubicin for the treatment of patients with advanced heaptocellular carcinoma: a phase I-II trial. Ann Oncol. 2002;13:1771-1778.
27. Lee JL, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004.
28. Llovet JM, Ruff P, Tassopoulos N, et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer. 2001;37:1352-1358.
29. Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol. 1985;15:559-562.
30. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamozifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109:917-922.
31. Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet. 1998;352:17-22.
32. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002;36:1221-1226.
33. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42:442-447.
34. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687-691.
35. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002;49:1245-1250.
36. Pan DY, Qiao JG, Huo YC, et al. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. HBPD Int. 2003;2:211-215.
37. Siveke JT, Herberhold C, Folwaczny C. Complete regression of HCC with long acting octreotide. Gut. 2003;42:442-447.
38. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR 1-5). Endocrinology. 1994;135:2814-2817.
39. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy. 2001;47:1-29.
40. Chen XJ, Liu ZS, Ai ZL. Antineoplastic mechanism of octreotide action in human hepatoma. China Med J. 2001;114:1167-1170.
41. Jia WD, Xu GL, Xu RN, et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 2003; 129:327-334.